AR105836A1 - Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk - Google Patents
Compuestos y composiciones útiles para tratar trastornos relacionados con ntrkInfo
- Publication number
- AR105836A1 AR105836A1 ARP160102616A ARP160102616A AR105836A1 AR 105836 A1 AR105836 A1 AR 105836A1 AR P160102616 A ARP160102616 A AR P160102616A AR P160102616 A ARP160102616 A AR P160102616A AR 105836 A1 AR105836 A1 AR 105836A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkylene
- heterocyclyl
- heteroalkyl
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Inhibidores de NTRK que son activos contra NTRK de tipo salvaje y sus mutantes resistentes. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, en donde: los anillos A y B se seleccionan cada uno independientemente de arilo, heteroarilo, cicloalquilo y heterociclilo; cada L¹ y L² se selecciona independientemente de un enlace, -C(O)-, -N(R¹)-, -N(R¹)-C(O)-, -C(O)-N(R¹)-, -(alquileno C₁₋₆)-N(R¹)-, -N(R¹)-(alquileno C₁₋₆)-, -N(R¹)-C(O)-(alquileno C₁₋₆)- y -C(O)-N(R¹)-(alquileno C₁₋₆)-; en donde cada parte de alquileno de L¹ y L² se sustituye independientemente con 0 - 5 apariciones de R; cada RA y RB se selecciona independientemente de hidroxilo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxilo C₁₋₆, halo, heteroalquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo, heterociclilalquilo, nitro, ciano, -C(O)R¹, -OC(O)R¹, -C(O)OR¹, -(alquileno C₁₋₆)-C(O)R¹, -SR¹, -S(O)₂R¹, -S(O)₂-N(R¹)(R¹), -(alquileno C₁₋₆)-S(O)₂R¹, -(alquileno C₁₋₆)-S(O)₂-N(R¹)(R¹), -N(R¹)(R¹), -C(O)-N(R¹)(R¹), -N(R¹)-C(O)R¹, -N(R¹)-C(O)OR¹, -(alquileno C₁₋₆)-N(R¹)-C(O)R¹, -N(R¹)S(O)₂R¹ y -P(O)(R¹)(R¹); en donde cada parte de alquilo alquenilo, .alquinilo, alcoxilo, heteroalquilo, haloalquilo, haloalcoxilo, hidroxialquilo, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo y heterociclilalquilo de cada uno de RA y RB se sustituye independientemente con 0 - 5 apariciones de Rᵃ; o 2 RA o 2 RB juntos con el átomo de carbono al cual están unidos forman un anillo cicloalquilo o heterociclilo sustituido independientemente con 0 - 5 apariciones de Rᵃ; cada R¹ se selecciona independientemente de hidrógeno, hidroxilo, halo, tiol, alquilo C₁₋₆, tioalquilo C₁₋₆, alcoxilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, heteroalquilo C₁₋₆, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, en donde cada parte de alquilo, tioalquilo, alcoxilo, haloalquilo, hidroxialquilo, heteroalquilo, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo de R¹ se sustituye independientemente con 0 - 5 apariciones de Rᵇ o 2 R¹ junto con los átomos a los cuales están unidos forman un anillo cicloalquilo o heterociclilo sustituido independientemente con 0 - 5 apariciones de Rᵇ; cada Rᵃ y Rᵇ se selecciona independientemente de alquilo C₁₋₆, halo, hidroxilo, haloalquilo C₁₋₆, heteroalquilo C₁₋₆, hidroxialquilo C₁₋₆, alcoxilo C₁₋₆, cicloalquilo, heterociclilo y ciano, en donde cada parte de alquilo, haloalquilo, heteroalquilo, hidroxialquilo, alcoxilo, cicloalquilo y heterociclilo de Rᵃ y Rᵇ se sustituye independientemente con 0 - 5 apariciones de R; cada R se selecciona independientemente de alquilo C₁₋₆, heteroalquilo C₁₋₆, halo, hidroxilo, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo y ciano; o 2 R junto con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; y p es 0, 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562210264P | 2015-08-26 | 2015-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105836A1 true AR105836A1 (es) | 2017-11-15 |
Family
ID=56896780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102616A AR105836A1 (es) | 2015-08-26 | 2016-08-26 | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk |
Country Status (17)
Country | Link |
---|---|
US (2) | US10017512B2 (es) |
EP (1) | EP3341374A1 (es) |
JP (1) | JP6877407B2 (es) |
KR (1) | KR20180043810A (es) |
CN (1) | CN108137607B (es) |
AR (1) | AR105836A1 (es) |
AU (1) | AU2016311426B2 (es) |
BR (1) | BR112018003588A2 (es) |
CA (1) | CA2995997A1 (es) |
HK (1) | HK1255330A1 (es) |
IL (1) | IL257702A (es) |
MX (1) | MX2018002407A (es) |
PH (1) | PH12018500397A1 (es) |
RU (1) | RU2744974C2 (es) |
TW (1) | TW201713665A (es) |
WO (1) | WO2017035354A1 (es) |
ZA (1) | ZA201801881B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62233B1 (sr) | 2012-07-11 | 2021-09-30 | Blueprint Medicines Corp | Inhibitori receptora fibroblast faktora rasta |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
EP3057969B1 (en) | 2013-10-17 | 2018-06-13 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
RU2018106483A (ru) | 2015-07-24 | 2019-08-26 | Блюпринт Медсинс Корпорейшн | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr |
JP6877407B2 (ja) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Ntrk関連障害の治療に有用な化合物および組成物 |
TWI757256B (zh) | 2015-11-02 | 2022-03-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
AU2018320021C1 (en) | 2017-08-23 | 2023-02-23 | Centaurus Biopharma Co., Ltd. | Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof |
JP7278273B2 (ja) | 2017-10-18 | 2023-05-19 | ブループリント メディシンズ コーポレイション | アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン |
CN111936138B (zh) * | 2018-02-05 | 2024-03-08 | 深圳市原力生命科学有限公司 | 作为ep4受体拮抗剂的杂二环化合物 |
WO2019184955A1 (en) * | 2018-03-28 | 2019-10-03 | Fochon Pharmaceuticals, Ltd. | Macrocyclic compounds as trk kinases inhibitors |
SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
AU2020228056A1 (en) * | 2019-02-27 | 2021-09-16 | Ferro Therapeutics, Inc. | Compounds with ferroptosis inducing activity and methods of their use |
CN113966334A (zh) | 2019-04-12 | 2022-01-21 | 缆图药品公司 | (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙烷-1-胺的晶形及制备方法 |
CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014450A1 (en) * | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
TWI344468B (en) | 2002-09-04 | 2011-07-01 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
MXPA06011423A (es) * | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
UY32192A (es) | 2008-10-22 | 2011-05-31 | Array Biopharma Inc | COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO INHIBIDORES DE TRK CINASA |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
CN102471342A (zh) * | 2010-05-05 | 2012-05-23 | 沃泰克斯药物股份有限公司 | 用作PKC-θ抑制剂的4取代的吡唑并吡啶类 |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
RS62233B1 (sr) | 2012-07-11 | 2021-09-30 | Blueprint Medicines Corp | Inhibitori receptora fibroblast faktora rasta |
JP6223451B2 (ja) * | 2012-08-31 | 2017-11-01 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト | がんの診断及び治療方法 |
CA2887203A1 (en) | 2012-10-05 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | 2,3-(hetero)aryl substituted pyridinyl compounds and their use as gdf-8 inhibitors |
CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
ES2653419T3 (es) * | 2013-02-01 | 2018-02-07 | Bayer Pharma Aktiengesellschaft | Pirazolopirimidinilamino-indazoles sustituidos |
CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
BR112015022545A2 (pt) | 2013-03-13 | 2017-07-18 | Constellation Pharmaceuticals Inc | compostos de pirazolo e os usos disso |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
EP3057969B1 (en) | 2013-10-17 | 2018-06-13 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
AU2015365587B2 (en) | 2014-12-15 | 2020-07-23 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as TRK inhibitors |
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
CN107531666A (zh) | 2015-02-20 | 2018-01-02 | 里格尔药品股份有限公司 | Gdf‑8抑制剂 |
RU2018106483A (ru) | 2015-07-24 | 2019-08-26 | Блюпринт Медсинс Корпорейшн | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr |
JP6877407B2 (ja) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Ntrk関連障害の治療に有用な化合物および組成物 |
TWI757256B (zh) | 2015-11-02 | 2022-03-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-08-25 JP JP2018510406A patent/JP6877407B2/ja active Active
- 2016-08-25 MX MX2018002407A patent/MX2018002407A/es unknown
- 2016-08-25 WO PCT/US2016/048698 patent/WO2017035354A1/en active Application Filing
- 2016-08-25 KR KR1020187008146A patent/KR20180043810A/ko unknown
- 2016-08-25 BR BR112018003588A patent/BR112018003588A2/pt not_active IP Right Cessation
- 2016-08-25 RU RU2018110379A patent/RU2744974C2/ru active
- 2016-08-25 CA CA2995997A patent/CA2995997A1/en not_active Abandoned
- 2016-08-25 CN CN201680060799.0A patent/CN108137607B/zh not_active Expired - Fee Related
- 2016-08-25 AU AU2016311426A patent/AU2016311426B2/en not_active Expired - Fee Related
- 2016-08-25 EP EP16763630.7A patent/EP3341374A1/en not_active Withdrawn
- 2016-08-26 TW TW105127561A patent/TW201713665A/zh unknown
- 2016-08-26 US US15/248,207 patent/US10017512B2/en active Active
- 2016-08-26 AR ARP160102616A patent/AR105836A1/es unknown
-
2018
- 2018-02-22 PH PH12018500397A patent/PH12018500397A1/en unknown
- 2018-02-25 IL IL257702A patent/IL257702A/en unknown
- 2018-03-20 ZA ZA2018/01881A patent/ZA201801881B/en unknown
- 2018-07-03 US US16/027,166 patent/US11046697B2/en active Active
- 2018-11-13 HK HK18114466.6A patent/HK1255330A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112018003588A2 (pt) | 2018-09-25 |
CN108137607A (zh) | 2018-06-08 |
TW201713665A (zh) | 2017-04-16 |
ZA201801881B (en) | 2019-05-29 |
IL257702A (en) | 2018-04-30 |
US11046697B2 (en) | 2021-06-29 |
KR20180043810A (ko) | 2018-04-30 |
US20170066773A1 (en) | 2017-03-09 |
US10017512B2 (en) | 2018-07-10 |
WO2017035354A1 (en) | 2017-03-02 |
JP6877407B2 (ja) | 2021-05-26 |
RU2744974C2 (ru) | 2021-03-17 |
AU2016311426B2 (en) | 2021-05-20 |
EP3341374A1 (en) | 2018-07-04 |
JP2018528200A (ja) | 2018-09-27 |
RU2018110379A3 (es) | 2019-12-26 |
AU2016311426A1 (en) | 2018-04-05 |
MX2018002407A (es) | 2018-11-29 |
US20190169194A1 (en) | 2019-06-06 |
PH12018500397A1 (en) | 2018-08-29 |
RU2018110379A (ru) | 2019-09-27 |
CA2995997A1 (en) | 2017-03-02 |
HK1255330A1 (zh) | 2019-08-16 |
CN108137607B (zh) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
AR107912A1 (es) | Inhibidores de ret | |
AR105459A1 (es) | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
AR104388A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
AR100233A1 (es) | Composición de limpieza | |
AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
AR106293A1 (es) | Moduladores del receptor x farnesoide | |
EA033294B1 (ru) | Пиридазиноновые гербициды | |
AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
PH12017501652A1 (en) | Kv1.3 inhibitors and their medical application | |
AR110440A1 (es) | Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina | |
AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona |